Jakob Anninga

2.3k total citations
20 papers, 834 citations indexed

About

Jakob Anninga is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Oncology. According to data from OpenAlex, Jakob Anninga has authored 20 papers receiving a total of 834 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 7 papers in Rheumatology and 5 papers in Oncology. Recurrent topics in Jakob Anninga's work include Sarcoma Diagnosis and Treatment (11 papers), Bone Tumor Diagnosis and Treatments (6 papers) and Cancer Genomics and Diagnostics (4 papers). Jakob Anninga is often cited by papers focused on Sarcoma Diagnosis and Treatment (11 papers), Bone Tumor Diagnosis and Treatments (6 papers) and Cancer Genomics and Diagnostics (4 papers). Jakob Anninga collaborates with scholars based in Netherlands, United Kingdom and Italy. Jakob Anninga's co-authors include Hans Gelderblom, Pancras C.W. Hogendoorn, Marta Fiocco, R. Maarten Egeler, A. H. M. Taminiau, Judith R. Kroep, Jelle J. Goeman, Hans C. van Houwelingen, Jan Oosting and Anne‐Marie Cleton‐Jansen and has published in prestigious journals such as International Journal of Radiation Oncology*Biology*Physics, European Journal of Cancer and BMJ Open.

In The Last Decade

Jakob Anninga

20 papers receiving 816 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jakob Anninga Netherlands	11	406	312	189	172	168	20	834
Brian D. Crompton United States	19	511 1.3×	520 1.7×	327 1.7×	88 0.5×	411 2.4×	57	1.2k
Vamsi Kota United States	19	136 0.3×	397 1.3×	408 2.2×	143 0.8×	131 0.8×	156	1.4k
Toshifumi Kurahashi Japan	17	476 1.2×	228 0.7×	272 1.4×	87 0.5×	150 0.9×	50	868
Ofelia Cruz Spain	17	199 0.5×	163 0.5×	183 1.0×	52 0.3×	62 0.4×	69	778
Deanna McLeod Canada	15	229 0.6×	222 0.7×	461 2.4×	61 0.4×	224 1.3×	26	793
Mariana M. Cajaiba United States	16	328 0.8×	470 1.5×	155 0.8×	62 0.4×	166 1.0×	43	923
Danielle Antin‐Ozerkis United States	13	659 1.6×	362 1.2×	148 0.8×	85 0.5×	113 0.7×	28	1.2k
Luisa Toffolatti Italy	18	653 1.6×	230 0.7×	278 1.5×	162 0.9×	102 0.6×	42	1.1k
Tina Mayer United States	12	323 0.8×	308 1.0×	321 1.7×	43 0.3×	190 1.1×	64	881
Nam Q. Bui United States	15	374 0.9×	178 0.6×	307 1.6×	85 0.5×	166 1.0×	80	766

Countries citing papers authored by Jakob Anninga

Since Specialization

Citations

This map shows the geographic impact of Jakob Anninga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jakob Anninga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jakob Anninga more than expected).

Fields of papers citing papers by Jakob Anninga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jakob Anninga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jakob Anninga. The network helps show where Jakob Anninga may publish in the future.

Co-authorship network of co-authors of Jakob Anninga

This figure shows the co-authorship network connecting the top 25 collaborators of Jakob Anninga. A scholar is included among the top collaborators of Jakob Anninga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jakob Anninga. Jakob Anninga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Geloven, Nan van, et al.. (2022). Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial. BMJ Open. 12(5). e052941–e052941. 2 indexed citations

Anninga, Jakob, et al.. (2022). Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trial. BMJ Open. 12(3). e053083–e053083. 7 indexed citations

Rueten‐Budde, Anja J., Marta Fiocco, Desirée M. J. Dorleijn, et al.. (2021). Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center. Cancers. 13(3). 486–486. 15 indexed citations

Hopman, Saskia, Corianne A.J.M. de Borgie, Cora M. Aalfs, et al.. (2021). Clinical value of a screening tool for tumor predisposition syndromes in childhood cancer patients (TuPS): a prospective, observational, multi-center study. Familial Cancer. 20(4). 263–271. 6 indexed citations

Ieva, Francesca, et al.. (2021). Novel longitudinal Multiple Overall Toxicity (MOTox) score to quantify adverse events experienced by patients during chemotherapy treatment: a retrospective analysis of the MRC BO06 trial in osteosarcoma. BMJ Open. 11(12). e053456–e053456. 3 indexed citations

Ven, Cornelis P. van de, Jakob Anninga, Christian Koelsche, et al.. (2021). Nodular Fasciitis With Malignant Morphology and a COL6A2–USP6 Fusion: A Case Report (of a 10-Year-old Boy). International Journal of Surgical Pathology. 29(6). 642–647. 8 indexed citations

Anninga, Jakob, Matthew R. Sydes, Cristian Spitoni, et al.. (2019). A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup. Cancer Chemotherapy and Pharmacology. 83(5). 951–962. 19 indexed citations

Anninga, Jakob, Cristian Spitoni, Matthew R. Sydes, et al.. (2019). Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma. BMJ Open. 9(5). e022980–e022980. 6 indexed citations

Spitoni, Cristian, Jakob Anninga, Jeremy Whelan, et al.. (2018). Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensity. Statistical Methods in Medical Research. 28(9). 2787–2801. 7 indexed citations

10.

Spitoni, Cristian, Jakob Anninga, Jeremy Whelan, et al.. (2017). Causal inference with randomised clinical trials of chemotherapy: The importance of well-documented treatment side-effects. Data Archiving and Networked Services (DANS). 1 indexed citations

11.

Oosterwijk, Jolieke G. van, Jakob Anninga, Hans Gelderblom, Anne‐Marie Cleton-Jansen, & Judith V.M.G. Bovée. (2013). Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma. Hematology/Oncology Clinics of North America. 27(5). 1021–1048. 60 indexed citations

12.

Anninga, Jakob. (2013). Clinical and molecular features of high-grade osteosarcoma. Data Archiving and Networked Services (DANS). 1 indexed citations

13.

Anninga, Jakob, Piero Picci, Marta Fiocco, et al.. (2012). Osteosarcoma of the hands and feet: a distinct clinico-pathological subgroup. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 462(1). 109–120. 21 indexed citations

14.

Buddingh, Emilie P., Dagmar Berghuis, Hans Gelderblom, et al.. (2012). Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients. Cancer Immunology Immunotherapy. 61(6). 941–947. 13 indexed citations

15.

Anninga, Jakob, Hans Gelderblom, Marta Fiocco, et al.. (2011). Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?. European Journal of Cancer. 47(16). 2431–2445. 316 indexed citations

16.

Engelen, Vivian, Hendrik M. Koopman, Symone Detmar, et al.. (2010). Health‐related quality of life after completion of successful treatment for childhood cancer. Pediatric Blood & Cancer. 56(4). 646–653. 37 indexed citations

17.

Buddingh, Emilie P., Jakob Anninga, Michel I.M. Versteegh, et al.. (2009). Prognostic factors in pulmonary metastasized high‐grade osteosarcoma. Pediatric Blood & Cancer. 54(2). 216–221. 72 indexed citations

18.

Goeman, Jelle J., Jan Oosting, Anne‐Marie Cleton‐Jansen, Jakob Anninga, & Hans C. van Houwelingen. (2005). Testing association of a pathway with survival using gene expression data. Computer applications in the biosciences. 21(9). 1950–1957. 118 indexed citations

19.

Anninga, Jakob, Marc J. van de Vijver, Anne‐Marie Cleton-Jansen, et al.. (2003). Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. European Journal of Cancer. 40(7). 963–970. 57 indexed citations

20.

Dewit, L., Jakob Anninga, C.A. Hoefnagel, & W J Nooijen. (1990). Radiation injury in the human kidney: A prospective analysis using specific scintigraphic and biochemical endpoints. International Journal of Radiation Oncology*Biology*Physics. 19(4). 977–983. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact